産品簡介:
Semaglutide 索馬魯肽
産品關鍵詞:
Semaglutide 索馬魯肽;Liraglutide利拉魯肽; GLP-1受體激動劑;Metformin HCl鹽酸二甲雙胍;Acarbose阿卡波糖;Antidiabetic drug抗糖尿病藥物(wù);Streptozotocin (STZ)鏈脲佐菌素;CAS:910463-68-2;
産品信息
産品名稱
|
産品編号
|
CAS NO.
|
規格
|
價格(元)
|
促銷價(元)
|
Semaglutide索馬魯肽
|
MZ7352-1MG
|
910463-68-2
|
1mg
|
1580
|
1422
|
Semaglutide索馬魯肽
|
MZ7352-5MG
|
910463-68-2
|
5mg
|
3980
|
3582
|
Semaglutide索馬魯肽
|
MZ7352-10MG
|
910463-68-2
|
10mg
|
5980
|
5382
|
【溫馨提示】:見(jiàn)我司(MKBio)的小(xiǎo)分子化合物(wù)常見(jiàn)問題-懋康生(shēng)物(wù)。
【溫馨提示】:見(jiàn)我司(MKBio)整理的糖尿病模型建立-鏈脲佐菌素(STZ)。
産品描述
索馬魯肽(Semaglutide)是一(yī)種胰高(gāo)血糖素樣肽-1(GLP-1) 受體激動劑,在表達人受體的BHK細胞報(bào)告基因實驗中,EC50=6.2 pM。在db/db小(xiǎo)鼠的II型糖尿病中,索馬魯肽可降低(dī)血糖水(shuǐ)平,以葡萄糖依賴的方式刺激胰島素和抑制胰高(gāo)血糖素分泌。索馬魯肽是比利拉魯肽(Liraglutide, MZ7351)更長(cháng)效的替代物(wù),結構上(shàng)類似于GLP-1。在MPTP誘導的帕金森模型中,索馬魯肽(25 nmol/kg)預防塞梅林氏神經節中多(duō)巴胺能(néng)神經元的減少,提高(gāo)塞梅林氏神經節和紋狀體中的脂質過氧化,以及改善滾軸實驗和足迹分析中動物(wù)的運動協調。索馬魯肽具抗肥胖活性。減低(dī)能(néng)量攝取,索馬魯肽誘導的體重減輕可能(néng)的作用機(jī)制包括:食欲降低(dī),更好的控制飲食和相(xiàng)對來說更低(dī)程度的嗜好脂肪和熱量較重的食物(wù)。
産品特性
1) CAS NO:910463-68-2
2) 序列:H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala- Lys(AEEAc-AEEAc-γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH
3) 同義名:Semaglutide free acid; NN 9535; NNC 0113-0217; Ozempic
4) 分子式:C187H291N45O59
5) 分子量:4113.58
6) 純度:≥98%
7) 外觀:白(bái)色粉末
8) 溶解性:溶于DMSO(3mg/ml)、不溶于乙醇和水(shuǐ)
保存與運輸方法
保存:2-8℃密封幹燥短期保存,長(cháng)期置于-20℃密封幹燥保存,至少2年(nián)有效。
運輸:冰袋運輸。
注意事(shì)項
1) 針對溶解性比較差的化合物(wù),可通(tōng)過≤60℃溫育和(或)超聲的方式來促進其溶解。不同批次化合物(wù)的溶解性會(huì)有差異,以實際測定為(wèi)準。
2) 本品配制的儲存液請盡快使用,若單次不能(néng)用完,請根據單次用量分裝,≤-20℃保存(-20℃ 一(yī)個(gè)月(yuè);-80℃ 六個(gè)月(yuè))。
3) 本品并非商業(yè)化的臨床藥物(wù),僅用作科研用途,不得用作臨床診斷或治療,不得用于食品或藥品,絕對禁止用在人身上(shàng)。
4) 為(wèi)了您的安全和健康,請穿實驗服并戴一(yī)次性手套操作。
配制儲存液
質量
溶劑體積
濃度
|
1mg
|
5mg
|
10mg
|
0.5mM
|
0.4862 mL
|
2.4310 mL
|
4.8619 mL
|
0.1mM
|
2.4310 mL
|
12.1549 mL
|
24.3097mL
|
使用方法【源自(zì)文獻,僅作參考】
文獻1,Rakipovski G, Rolin B, Nøhr J, Klewe I, Frederiksen KS, Augustin R, Hecksher-Sørensen J, Ingvorsen C, Polex-Wolf J, Knudsen LB. The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways. JACC Basic Transl Sci. 2018 Nov 21;3(6):844-857. doi: 10.1016/j.jacbts.2018.09.004. PMID: 30623143; PMCID: PMC6314963.
體内研究(動物(wù)模型):
動物(wù)模型(Animal Model):C57BL/6J lean male mice at 12 weeks of age
實驗方法(Assay):To studyacute inflammation in vivo study design, C57BL/6J lean male mice at 12 weeks of age were givenSC doses of semaglutide (60.0 μg/kg) or vehicle control 1 hour prior to receiving an IP dose of lipopolysaccharide (LPS) (0.05 mg/kg, Escherichia coli O55:B5) or vehicle control.Blood samples were collected from the sinus orbital vein at 1 and 4 h after LPS dose.
|
文獻2,Wang L, Ding J, Zhu C, Guo B, Yang W, He W, Li X, Wang Y, Li W, Wang F, Wang F, et al: Semaglutide attenuates seizure severity and ameliorates cognitive dysfunction by blocking the NLR family pyrin domain containing 3 inflammasome in pentylenetetrazole‑kindled mice. Int J Mol Med 48: 219, 2021
體外研究:
細胞類型(Cell type):BV2 cells
實驗方法(Assay): BV2 cells were seeded into 96-well plates (1×104 cells/well) for 12 h, and thentreated with different doses (300, 600, 900 or 1,000 nM) of semaglutide for 20 h at 37°C. A blank well with culture medium was used to detect background, and five replicate wells were established per group. CCK-8 reagent (100 µl) was added toevaluate cellular proliferation.
體内研究(動物(wù)模型):
動物(wù)模型(Animal Model):C57BL/6J mice (male, 10±2 weeks old; weight, 25±3 g)
實驗方法(Assay):The animals were randomized into five groups (20 per group), all of which were treated by intraperitoneal (i.p.) injection. In the control group (1% DMSO, i.p.), mice received 20 injections in total - 19 injections every other day for 37 days, and a final injection on the 45th day.For the semaglutide group [25 nM/kg semaglutide i.p.], the administration schedule was the same as that for the control group. In the PTZ group [37 mg/kg PTZ, i.p.], the mice received a total of 16 injections - one injection every other day from the 9th to the 37th day for a total of 15 injections, and a final injection on the 45th day.For the low-dose semaglutide group [37 mg/kg PTZ + 10 nM/kg semaglutide, i.p.], the semaglutide administration schedule was the same as that for the control group, and the PTZ administration schedule was the same as that for the PTZ group, 30 min after each injection of semaglutide.For the high-dose semaglutide group (37 mg/kg PTZ + 25 nM/kg semaglutide, i.p.), the administration schedule was the same as that for the low-dose semaglutide group.
|
相(xiàng)關産品
貨号
|
名稱
|
規格
|
MZ7351-1MG
|
Liraglutide利拉魯肽
|
1mg
|
MZ7352-1MG
|
Semaglutide索馬魯肽
|
1mg
|
MZ3403-1G
|
Metformin Hydrochloride鹽酸二甲雙胍
|
1g
|
MZ99023-1G
|
Acarbose阿卡波糖
|
1g
|
MS1601-100MG
|
Streptozotocin (STZ)鏈脲佐菌素
|
100mg
|
— —Written/Edited by V. Shallan【版權歸MKBio懋康所有】
上海夢澤生物科技有限公司是一(yī)家涉足于生(shēng)命科學和生(shēng)物(wù)技(jì)術(shù)領域研究的試劑、儀器(qì)和實驗室消耗品與實驗服務工(gōng)作,主要從(cóng)事(shì)細胞生(shēng)物(wù)學、植物(wù)學、分子生(shēng)物(wù)學、免疫學、生(shēng)物(wù)化學、蛋白(bái)組學。生(shēng)物(wù)制藥與診斷試劑研發生(shēng)産等領域。 本公司秉承“以人為(wèi)本,以誠為(wèi)信、合同守信”的經營理念。堅持"品質保障"的原則為(wèi)廣大客戶提供優質産品。
|